ID   BARD1_HUMAN             Reviewed;         777 AA.
AC   Q99728; F6MDH7; F6MDH8; F6MDH9; O43574; Q53SS5;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   10-MAY-2017, entry version 186.
DE   RecName: Full=BRCA1-associated RING domain protein 1;
DE            Short=BARD-1;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:20351172};
DE   AltName: Full=RING-type E3 ubiquitin transferase BARD1 {ECO:0000305};
GN   Name=BARD1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION.
RC   TISSUE=B-cell;
RX   PubMed=8944023; DOI=10.1038/ng1296-430;
RA   Wu L.C., Wang Z.W., Tsan J.T., Spillman M.A., Phung A., Xu X.L.,
RA   Yang M.-C.W., Hwang L.-Y., Bowcock A.M., Baer R.;
RT   "Identification of a RING protein that can interact in vivo with the
RT   BRCA1 gene product.";
RL   Nat. Genet. 14:430-440(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-24; GLU-153;
RP   SER-378; MET-507; SER-557; HIS-564; CYS-658; LEU-695 AND ASN-761.
RX   PubMed=9425226; DOI=10.1093/hmg/7.2.195;
RA   Thai T.H., Du F., Tsan J.T., Jin Y., Phung A., Spillman M.A.,
RA   Massa H.F., Muller C.Y., Ashfaq R., Mathis J.M., Miller D.S.,
RA   Trask B.J., Baer R., Bowcock A.M.;
RT   "Mutations in the BRCA1-associated RING domain (BARD1) gene in primary
RT   breast, ovarian and uterine cancers.";
RL   Hum. Mol. Genet. 7:195-202(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA; BETA AND GAMMA), AND
RP   ALTERNATIVE SPLICING.
RX   PubMed=18089818; DOI=10.1158/0008-5472.CAN-07-2370;
RA   Li L., Ryser S., Dizin E., Pils D., Krainer M., Jefford C.E.,
RA   Bertoni F., Zeillinger R., Irminger-Finger I.;
RT   "Oncogenic BARD1 isoforms expressed in gynecological cancers.";
RL   Cancer Res. 67:11876-11885(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   DOMAINS.
RX   PubMed=10026184; DOI=10.1074/jbc.274.9.5659;
RA   Meza J.E., Brzovic P.S., King M.-C., Klevit R.E.;
RT   "Mapping the functional domains of BRCA1. Interaction of the ring
RT   finger domains of BRCA1 and BARD1.";
RL   J. Biol. Chem. 274:5659-5665(1999).
RN   [7]
RP   POSSIBLE FUNCTION.
RX   PubMed=10477523; DOI=10.1126/science.285.5433.1576;
RA   Kleiman F.E., Manley J.L.;
RT   "Functional interaction of BRCA1-associated BARD1 with polyadenylation
RT   factor CstF-50.";
RL   Science 285:1576-1579(1999).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH BRCA1.
RX   PubMed=12890688; DOI=10.1074/jbc.C300249200;
RA   Wu-Baer F., Lagrazon K., Yuan W., Baer R.;
RT   "The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an
RT   unconventional linkage involving lysine residue K6 of ubiquitin.";
RL   J. Biol. Chem. 278:34743-34746(2003).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH BRCA1.
RX   PubMed=14976165; DOI=10.1093/hmg/ddh095;
RA   Morris J.R., Solomon E.;
RT   "BRCA1:BARD1 induces the formation of conjugated ubiquitin structures,
RT   dependent on K6 of ubiquitin, in cells during DNA replication and
RT   repair.";
RL   Hum. Mol. Genet. 13:807-817(2004).
RN   [10]
RP   IDENTIFICATION IN THE BRCA1-A COMPLEX.
RX   PubMed=17643122; DOI=10.1038/nsmb1277;
RA   Kim H., Huang J., Chen J.;
RT   "CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA
RT   damage response.";
RL   Nat. Struct. Mol. Biol. 14:710-715(2007).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-391 AND THR-394, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   IDENTIFICATION IN THE BRCA1-A COMPLEX.
RX   PubMed=19261749; DOI=10.1101/gad.1770309;
RA   Wang B., Hurov K., Hofmann K., Elledge S.J.;
RT   "NBA1, a new player in the Brca1 A complex, is required for DNA damage
RT   resistance and checkpoint control.";
RL   Genes Dev. 23:729-739(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH BRCA1.
RX   PubMed=20351172; DOI=10.1128/MCB.01056-09;
RA   Wu-Baer F., Ludwig T., Baer R.;
RT   "The UBXN1 protein associates with autoubiquitinated forms of the
RT   BRCA1 tumor suppressor and inhibits its enzymatic function.";
RL   Mol. Cell. Biol. 30:2787-2798(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-186 AND THR-299, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-170, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [18]
RP   STRUCTURE BY NMR OF 26-140 IN COMPLEX WITH BRCA1 AND ZINC IONS, AND
RP   SUBUNIT.
RX   PubMed=11573085; DOI=10.1038/nsb1001-833;
RA   Brzovic P.S., Rajagopal P., Hoyt D.W., King M.C., Klevit R.E.;
RT   "Structure of a BRCA1-BARD1 heterodimeric RING-RING complex.";
RL   Nat. Struct. Biol. 8:833-837(2001).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 568-777.
RX   PubMed=17550235; DOI=10.1021/bi700323t;
RA   Birrane G., Varma A.K., Soni A., Ladias J.A.;
RT   "Crystal structure of the BARD1 BRCT domains.";
RL   Biochemistry 46:7706-7712(2007).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 569-777, INTERACTION WITH
RP   CSTF1, DOMAIN STRUCTURE, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18842000; DOI=10.1021/bi801115g;
RA   Edwards R.A., Lee M.S., Tsutakawa S.E., Williams R.S., Nazeer I.,
RA   Kleiman F.E., Tainer J.A., Glover J.N.;
RT   "The BARD1 C-terminal domain structure and interactions with
RT   polyadenylation factor CstF-50.";
RL   Biochemistry 47:11446-11456(2008).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 425-555, IDENTIFICATION BY
RP   MASS SPECTROMETRY, DOMAINS ANK REPEATS, AND DOMAIN STRUCTURE.
RX   PubMed=18480049; DOI=10.1074/jbc.M802333200;
RA   Fox D. III, Le Trong I., Rajagopal P., Brzovic P.S., Stenkamp R.E.,
RA   Klevit R.E.;
RT   "Crystal structure of the BARD1 ankyrin repeat domain and its
RT   functional consequences.";
RL   J. Biol. Chem. 283:21179-21186(2008).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase. The BRCA1-BARD1 heterodimer
CC       specifically mediates the formation of 'Lys-6'-linked
CC       polyubiquitin chains and coordinates a diverse range of cellular
CC       pathways such as DNA damage repair, ubiquitination and
CC       transcriptional regulation to maintain genomic stability. Plays a
CC       central role in the control of the cell cycle in response to DNA
CC       damage. Acts by mediating ubiquitin E3 ligase activity that is
CC       required for its tumor suppressor function. Also forms a
CC       heterodimer with CSTF1/CSTF-50 to modulate mRNA processing and
CC       RNAP II stability by inhibiting pre-mRNA 3' cleavage.
CC       {ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:14976165,
CC       ECO:0000269|PubMed:20351172}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:12890688,
CC       ECO:0000269|PubMed:20351172}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Homo- and heterodimer. Heterodimer (RING-type zinc
CC       finger) with BRCA1. Heterodimer (via ANK repeats and BRCT domains)
CC       with CSTF1/CSTF-50. Component of the BRCA1-A complex, at least
CC       composed of the BRCA1, BARD1, UIMC1/RAP80, FAM175A/Abraxas,
CC       BRCC3/BRCC36, BRE/BRCC45 and BABAM1/NBA1. Interacts with UBXN1.
CC       {ECO:0000269|PubMed:11573085, ECO:0000269|PubMed:12890688,
CC       ECO:0000269|PubMed:14976165, ECO:0000269|PubMed:17643122,
CC       ECO:0000269|PubMed:18842000, ECO:0000269|PubMed:19261749,
CC       ECO:0000269|PubMed:20351172}.
CC   -!- INTERACTION:
CC       P38398:BRCA1; NbExp=9; IntAct=EBI-473181, EBI-349905;
CC       Q9P2H0:CEP126; NbExp=2; IntAct=EBI-473181, EBI-473176;
CC       Q8NHQ1:CEP70; NbExp=3; IntAct=EBI-473181, EBI-739624;
CC       Q12873:CHD3; NbExp=2; IntAct=EBI-473181, EBI-523590;
CC       Q05048:CSTF1; NbExp=4; IntAct=EBI-473181, EBI-1789619;
CC       P33240:CSTF2; NbExp=8; IntAct=EBI-473181, EBI-711360;
CC       Q8IW24:EXOC5; NbExp=3; IntAct=EBI-473181, EBI-10171392;
CC       Q8IZU0:FAM9B; NbExp=3; IntAct=EBI-473181, EBI-10175124;
CC       Q9Y2X7:GIT1; NbExp=2; IntAct=EBI-473181, EBI-466061;
CC       Q08379:GOLGA2; NbExp=3; IntAct=EBI-473181, EBI-618309;
CC       O95251:KAT7; NbExp=2; IntAct=EBI-473181, EBI-473199;
CC       Q6A162:KRT40; NbExp=3; IntAct=EBI-473181, EBI-10171697;
CC       O95751:LDOC1; NbExp=5; IntAct=EBI-473181, EBI-740738;
CC       O95453:PARN; NbExp=4; IntAct=EBI-473181, EBI-372832;
CC       O14776:TCERG1; NbExp=2; IntAct=EBI-473181, EBI-473271;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Note=During S phase of the cell
CC       cycle, colocalizes with BRCA1 into discrete subnuclear foci. Can
CC       translocate to the cytoplasm. Localizes at sites of DNA damage at
CC       double-strand breaks (DSBs); recruitment to DNA damage sites is
CC       mediated by the BRCA1-A complex.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=FL;
CC         IsoId=Q99728-1; Sequence=Displayed;
CC       Name=alpha;
CC         IsoId=Q99728-2; Sequence=VSP_055876;
CC       Name=beta;
CC         IsoId=Q99728-3; Sequence=VSP_055874, VSP_055875;
CC       Name=gamma;
CC         IsoId=Q99728-4; Sequence=VSP_055877, VSP_055878;
CC   -!- PTM: Processed during apoptosis. The homodimer is more susceptible
CC       to proteolytic cleavage than the BARD1/BRCA1 heterodimer.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-26 is the initiator.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BARD1ID756ch2q35.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U76638; AAB38316.1; -; mRNA.
DR   EMBL; AF038042; AAB99978.1; -; Genomic_DNA.
DR   EMBL; AF038034; AAB99978.1; JOINED; Genomic_DNA.
DR   EMBL; AF038035; AAB99978.1; JOINED; Genomic_DNA.
DR   EMBL; AF038036; AAB99978.1; JOINED; Genomic_DNA.
DR   EMBL; AF038037; AAB99978.1; JOINED; Genomic_DNA.
DR   EMBL; AF038038; AAB99978.1; JOINED; Genomic_DNA.
DR   EMBL; AF038039; AAB99978.1; JOINED; Genomic_DNA.
DR   EMBL; AF038040; AAB99978.1; JOINED; Genomic_DNA.
DR   EMBL; AF038041; AAB99978.1; JOINED; Genomic_DNA.
DR   EMBL; JF790280; AEF57471.1; -; mRNA.
DR   EMBL; JF790281; AEF57472.1; -; mRNA.
DR   EMBL; JF790282; AEF57473.1; -; mRNA.
DR   EMBL; AC016708; AAX93130.1; -; Genomic_DNA.
DR   EMBL; BC126426; AAI26427.1; -; mRNA.
DR   CCDS; CCDS2397.1; -. [Q99728-1]
DR   CCDS; CCDS74646.1; -. [Q99728-2]
DR   RefSeq; NP_000456.2; NM_000465.3. [Q99728-1]
DR   RefSeq; NP_001269472.1; NM_001282543.1. [Q99728-2]
DR   UniGene; Hs.591642; -.
DR   UniGene; Hs.597413; -.
DR   PDB; 1JM7; NMR; -; B=26-140.
DR   PDB; 2NTE; X-ray; 1.90 A; A/B=568-777.
DR   PDB; 2R1Z; X-ray; 2.10 A; A/B=569-777.
DR   PDB; 3C5R; X-ray; 2.00 A; A/B=425-555.
DR   PDB; 3FA2; X-ray; 2.20 A; A/B=566-777.
DR   PDBsum; 1JM7; -.
DR   PDBsum; 2NTE; -.
DR   PDBsum; 2R1Z; -.
DR   PDBsum; 3C5R; -.
DR   PDBsum; 3FA2; -.
DR   ProteinModelPortal; Q99728; -.
DR   SMR; Q99728; -.
DR   BioGrid; 107056; 268.
DR   DIP; DIP-5972N; -.
DR   IntAct; Q99728; 45.
DR   MINT; MINT-207047; -.
DR   STRING; 9606.ENSP00000260947; -.
DR   BindingDB; Q99728; -.
DR   iPTMnet; Q99728; -.
DR   PhosphoSitePlus; Q99728; -.
DR   BioMuta; BARD1; -.
DR   DMDM; 116241265; -.
DR   EPD; Q99728; -.
DR   MaxQB; Q99728; -.
DR   PaxDb; Q99728; -.
DR   PeptideAtlas; Q99728; -.
DR   PRIDE; Q99728; -.
DR   Ensembl; ENST00000260947; ENSP00000260947; ENSG00000138376. [Q99728-1]
DR   Ensembl; ENST00000617164; ENSP00000480470; ENSG00000138376. [Q99728-2]
DR   Ensembl; ENST00000620057; ENSP00000481988; ENSG00000138376. [Q99728-4]
DR   GeneID; 580; -.
DR   KEGG; hsa:580; -.
DR   UCSC; uc002veu.4; human. [Q99728-1]
DR   CTD; 580; -.
DR   DisGeNET; 580; -.
DR   GeneCards; BARD1; -.
DR   H-InvDB; HIX0030010; -.
DR   HGNC; HGNC:952; BARD1.
DR   HPA; CAB034106; -.
DR   HPA; HPA035354; -.
DR   HPA; HPA044864; -.
DR   MalaCards; BARD1; -.
DR   MIM; 601593; gene.
DR   neXtProt; NX_Q99728; -.
DR   OpenTargets; ENSG00000138376; -.
DR   Orphanet; 145; Hereditary breast and ovarian cancer syndrome.
DR   PharmGKB; PA25256; -.
DR   eggNOG; KOG0504; Eukaryota.
DR   eggNOG; KOG4362; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   GeneTree; ENSGT00760000119090; -.
DR   HOGENOM; HOG000237306; -.
DR   HOVERGEN; HBG050662; -.
DR   InParanoid; Q99728; -.
DR   KO; K10683; -.
DR   OMA; KKNSIKM; -.
DR   OrthoDB; EOG091G0JNZ; -.
DR   PhylomeDB; Q99728; -.
DR   TreeFam; TF326440; -.
DR   Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA).
DR   Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR).
DR   Reactome; R-HSA-5689603; UCH proteinases.
DR   Reactome; R-HSA-5689901; Metalloprotease DUBs.
DR   Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA).
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates.
DR   Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ).
DR   Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange.
DR   Reactome; R-HSA-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   SignaLink; Q99728; -.
DR   SIGNOR; Q99728; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; BARD1; human.
DR   EvolutionaryTrace; Q99728; -.
DR   GeneWiki; BARD1; -.
DR   GenomeRNAi; 580; -.
DR   PRO; PR:Q99728; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000138376; -.
DR   CleanEx; HS_BARD1; -.
DR   ExpressionAtlas; Q99728; baseline and differential.
DR   Genevisible; Q99728; HS.
DR   GO; GO:0070531; C:BRCA1-A complex; IDA:UniProtKB.
DR   GO; GO:0031436; C:BRCA1-BARD1 complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000932; C:P-body; IDA:HPA.
DR   GO; GO:0000151; C:ubiquitin ligase complex; NAS:UniProtKB.
DR   GO; GO:0019900; F:kinase binding; NAS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:MGI.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; NAS:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0007050; P:cell cycle arrest; NAS:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; NAS:UniProtKB.
DR   GO; GO:0000729; P:DNA double-strand break processing; TAS:Reactome.
DR   GO; GO:0006260; P:DNA replication; TAS:Reactome.
DR   GO; GO:0000731; P:DNA synthesis involved in DNA repair; TAS:Reactome.
DR   GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0031441; P:negative regulation of mRNA 3'-end processing; NAS:UniProtKB.
DR   GO; GO:0046826; P:negative regulation of protein export from nucleus; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; NAS:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0085020; P:protein K6-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; NAS:UniProtKB.
DR   GO; GO:0042325; P:regulation of phosphorylation; IMP:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0000732; P:strand displacement; TAS:Reactome.
DR   GO; GO:0001894; P:tissue homeostasis; TAS:UniProtKB.
DR   CDD; cd00027; BRCT; 2.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 1.25.40.20; -; 2.
DR   Gene3D; 3.30.40.10; -; 1.
DR   Gene3D; 3.40.50.10190; -; 2.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR033097; BARD1.
DR   InterPro; IPR001357; BRCT_dom.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR24171:SF15; PTHR24171:SF15; 1.
DR   Pfam; PF12796; Ank_2; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   SMART; SM00248; ANK; 3.
DR   SMART; SM00292; BRCT; 2.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF52113; SSF52113; 2.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 3.
DR   PROSITE; PS50172; BRCT; 2.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ANK repeat; Complete proteome;
KW   DNA damage; DNA repair; Isopeptide bond; Metal-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    777       BRCA1-associated RING domain protein 1.
FT                                /FTId=PRO_0000055819.
FT   REPEAT      427    459       ANK 1.
FT   REPEAT      460    492       ANK 2.
FT   REPEAT      493    525       ANK 3.
FT   REPEAT      526    546       ANK 4; degenerate.
FT   DOMAIN      560    653       BRCT 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00033}.
FT   DOMAIN      667    777       BRCT 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00033}.
FT   ZN_FING      50     87       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION       26    119       Interaction with BRCA1.
FT   REGION      554    558       Flexible linker.
FT   COMPBIAS    400    403       Poly-Ser.
FT   COMPBIAS    542    545       Poly-Leu.
FT   MOD_RES     186    186       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     299    299       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     391    391       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     394    394       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   CROSSLNK    170    170       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25755297}.
FT   VAR_SEQ       1     24       MPDNRQPRNRQPRIRSGNEPRSAP -> MVAVPGPTVAPRS
FT                                TAWRSCCAARV (in isoform beta).
FT                                {ECO:0000303|PubMed:18089818}.
FT                                /FTId=VSP_055874.
FT   VAR_SEQ      25    121       Missing (in isoform beta).
FT                                {ECO:0000303|PubMed:18089818}.
FT                                /FTId=VSP_055875.
FT   VAR_SEQ      54     72       Missing (in isoform alpha).
FT                                {ECO:0000303|PubMed:18089818}.
FT                                /FTId=VSP_055876.
FT   VAR_SEQ     122    127       DLKEDK -> GRHTFC (in isoform gamma).
FT                                {ECO:0000303|PubMed:18089818}.
FT                                /FTId=VSP_055877.
FT   VAR_SEQ     128    777       Missing (in isoform gamma).
FT                                {ECO:0000303|PubMed:18089818}.
FT                                /FTId=VSP_055878.
FT   VARIANT      24     24       P -> S (common polymorphism in
FT                                Caucasians; less frequent in Africans;
FT                                dbSNP:rs1048108).
FT                                {ECO:0000269|PubMed:9425226}.
FT                                /FTId=VAR_010354.
FT   VARIANT     153    153       K -> E (in dbSNP:rs753377280).
FT                                {ECO:0000269|PubMed:9425226}.
FT                                /FTId=VAR_010355.
FT   VARIANT     186    186       S -> G (in dbSNP:rs16852741).
FT                                /FTId=VAR_038371.
FT   VARIANT     241    241       S -> C (in dbSNP:rs3738885).
FT                                /FTId=VAR_020109.
FT   VARIANT     378    378       R -> S (in dbSNP:rs2229571).
FT                                {ECO:0000269|PubMed:9425226}.
FT                                /FTId=VAR_024611.
FT   VARIANT     507    507       V -> M (in dbSNP:rs2070094).
FT                                {ECO:0000269|PubMed:9425226}.
FT                                /FTId=VAR_010356.
FT   VARIANT     557    557       C -> S (rare polymorphism in Caucasians;
FT                                dbSNP:rs28997576).
FT                                {ECO:0000269|PubMed:9425226}.
FT                                /FTId=VAR_010357.
FT   VARIANT     564    564       Q -> H (in an ovarian clear cell
FT                                adenocarcinoma).
FT                                {ECO:0000269|PubMed:9425226}.
FT                                /FTId=VAR_010358.
FT   VARIANT     645    645       C -> R (in dbSNP:rs34744268).
FT                                /FTId=VAR_038372.
FT   VARIANT     658    658       R -> C (rare polymorphism in Caucasians;
FT                                absent in Africans; dbSNP:rs3738888).
FT                                {ECO:0000269|PubMed:9425226}.
FT                                /FTId=VAR_010359.
FT   VARIANT     695    695       V -> L (in a breast cancer sample;
FT                                somatic mutation; dbSNP:rs111367604).
FT                                {ECO:0000269|PubMed:9425226}.
FT                                /FTId=VAR_010360.
FT   VARIANT     728    728       S -> F (in dbSNP:rs13389423).
FT                                /FTId=VAR_028309.
FT   VARIANT     761    761       S -> N (in an uterine cancer sample;
FT                                somatic mutation; dbSNP:rs142155101).
FT                                {ECO:0000269|PubMed:9425226}.
FT                                /FTId=VAR_010361.
FT   CONFLICT     85     85       V -> A (in Ref. 3; AEF57473).
FT                                {ECO:0000305}.
FT   CONFLICT    406    406       R -> Q (in Ref. 1; AAB38316 and 3;
FT                                AEF57471/AEF57472). {ECO:0000305}.
FT   HELIX        35     46       {ECO:0000244|PDB:1JM7}.
FT   STRAND       51     53       {ECO:0000244|PDB:1JM7}.
FT   STRAND       65     67       {ECO:0000244|PDB:1JM7}.
FT   TURN         72     74       {ECO:0000244|PDB:1JM7}.
FT   HELIX        75     78       {ECO:0000244|PDB:1JM7}.
FT   TURN         79     81       {ECO:0000244|PDB:1JM7}.
FT   STRAND       84     86       {ECO:0000244|PDB:1JM7}.
FT   HELIX        99    116       {ECO:0000244|PDB:1JM7}.
FT   HELIX       431    438       {ECO:0000244|PDB:3C5R}.
FT   HELIX       441    449       {ECO:0000244|PDB:3C5R}.
FT   HELIX       464    470       {ECO:0000244|PDB:3C5R}.
FT   HELIX       474    482       {ECO:0000244|PDB:3C5R}.
FT   HELIX       492    494       {ECO:0000244|PDB:3C5R}.
FT   HELIX       497    503       {ECO:0000244|PDB:3C5R}.
FT   HELIX       507    515       {ECO:0000244|PDB:3C5R}.
FT   HELIX       530    533       {ECO:0000244|PDB:3C5R}.
FT   HELIX       537    543       {ECO:0000244|PDB:3C5R}.
FT   STRAND      571    576       {ECO:0000244|PDB:2NTE}.
FT   HELIX       579    591       {ECO:0000244|PDB:2NTE}.
FT   STRAND      595    599       {ECO:0000244|PDB:2NTE}.
FT   STRAND      606    613       {ECO:0000244|PDB:2NTE}.
FT   HELIX       618    625       {ECO:0000244|PDB:2NTE}.
FT   STRAND      629    632       {ECO:0000244|PDB:2NTE}.
FT   HELIX       634    642       {ECO:0000244|PDB:2NTE}.
FT   HELIX       648    650       {ECO:0000244|PDB:2NTE}.
FT   HELIX       656    665       {ECO:0000244|PDB:2NTE}.
FT   TURN        671    674       {ECO:0000244|PDB:2NTE}.
FT   STRAND      676    679       {ECO:0000244|PDB:2NTE}.
FT   STRAND      684    686       {ECO:0000244|PDB:2NTE}.
FT   HELIX       688    697       {ECO:0000244|PDB:2NTE}.
FT   STRAND      701    705       {ECO:0000244|PDB:2NTE}.
FT   HELIX       709    711       {ECO:0000244|PDB:2NTE}.
FT   HELIX       713    715       {ECO:0000244|PDB:2NTE}.
FT   HELIX       729    731       {ECO:0000244|PDB:2NTE}.
FT   STRAND      735    739       {ECO:0000244|PDB:2NTE}.
FT   STRAND      750    752       {ECO:0000244|PDB:2NTE}.
FT   STRAND      755    759       {ECO:0000244|PDB:2NTE}.
FT   HELIX       760    769       {ECO:0000244|PDB:2NTE}.
SQ   SEQUENCE   777 AA;  86648 MW;  95E2D904046B5646 CRC64;
     MPDNRQPRNR QPRIRSGNEP RSAPAMEPDG RGAWAHSRAA LDRLEKLLRC SRCTNILREP
     VCLGGCEHIF CSNCVSDCIG TGCPVCYTPA WIQDLKINRQ LDSMIQLCSK LRNLLHDNEL
     SDLKEDKPRK SLFNDAGNKK NSIKMWFSPR SKKVRYVVSK ASVQTQPAIK KDASAQQDSY
     EFVSPSPPAD VSERAKKASA RSGKKQKKKT LAEINQKWNL EAEKEDGEFD SKEESKQKLV
     SFCSQPSVIS SPQINGEIDL LASGSLTESE CFGSLTEVSL PLAEQIESPD TKSRNEVVTP
     EKVCKNYLTS KKSLPLENNG KRGHHNRLSS PISKRCRTSI LSTSGDFVKQ TVPSENIPLP
     ECSSPPSCKR KVGGTSGRKN SNMSDEFISL SPGTPPSTLS SSSYRRVMSS PSAMKLLPNM
     AVKRNHRGET LLHIASIKGD IPSVEYLLQN GSDPNVKDHA GWTPLHEACN HGHLKVVELL
     LQHKALVNTT GYQNDSPLHD AAKNGHVDIV KLLLSYGASR NAVNIFGLRP VDYTDDESMK
     SLLLLPEKNE SSSASHCSVM NTGQRRDGPL VLIGSGLSSE QQKMLSELAV ILKAKKYTEF
     DSTVTHVVVP GDAVQSTLKC MLGILNGCWI LKFEWVKACL RRKVCEQEEK YEIPEGPRRS
     RLNREQLLPK LFDGCYFYLW GTFKHHPKDN LIKLVTAGGG QILSRKPKPD SDVTQTINTV
     AYHARPDSDQ RFCTQYIIYE DLCNYHPERV RQGKVWKAPS SWFIDCVMSF ELLPLDS
//
